Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
FDA Pre-Submission Meetings
FDA Pre-Submission Meetings
by violet
for 510(k) Submissions. Consultants and RA Experts...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by felicity
. Kathy Gilmartin, MSN, CRNP, CCRC. ...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by min-jolicoeur
. Kathy Gilmartin, MSN, CRN...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by tawny-fly
. Kathy Gilmartin, MSN, CRN...
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for S
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for S
by kittie-lecroy
Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2....
Post-FDA Approval, Initial US Clinical Experience with Watc
Post-FDA Approval, Initial US Clinical Experience with Watc
by phoebe-click
Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2....
What is FDA
What is FDA
by adriel473
. FDA. 10. The . Food . and . Drug . Administratio...
FDA Regulatory Requirements for Successful Biomarker Applications
FDA Regulatory Requirements for Successful Biomarker Applications
by oliver
Early Detection Research Network. September 9, 201...
FDA’s Access Mechanisms
FDA’s Access Mechanisms
by roxanne
When They Work – When They Don’t . And Why. St...
The FDA is Coming Neala Lane, MS, CCRC
The FDA is Coming Neala Lane, MS, CCRC
by joy
Associate Director. Quality Improvement Office. Of...
SHEDDING LIGHT ON AN FDA VISIT
SHEDDING LIGHT ON AN FDA VISIT
by CuteAsACupcake
Joyce Nancarrow Tull, MSN, RN, CCRP. University of...
FDA Perspective on the development and use of
FDA Perspective on the development and use of
by osullivan
Epidemiological cut-off values (ECVs). Simone M. S...
FDA's role in the innovation and
FDA's role in the innovation and
by josephine
evaluation of evolving . computer-aided diagnosis ...
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
FDA’s Center for Devices and Radiological Health: Current Status and Future Direction
by carny
Jeff Shuren, MD, JD. Center for Devices and Radiol...
FDA Overview of the Process for Clearance and Approval of Mass Spectrometry-based In vitro Diagnost
FDA Overview of the Process for Clearance and Approval of Mass Spectrometry-based In vitro Diagnost
by tatiana-dople
MSACL. April 4, 2019. Majda Haznadar, Kris Roth, ...
Modeling and Simulation at U.S. FDA
Modeling and Simulation at U.S. FDA
by debby-jeon
Tina Morrison, Ph.D.. Chair, Modeling and Simulat...
1 FDA’s BIMO Inspection Program
1 FDA’s BIMO Inspection Program
by olivia-moreira
and. IRB Inspections. VA IRB Chairs Meeting. Aug...
Digital health technology-derived clinical outcome assessments: considerations for regulatory decis
Digital health technology-derived clinical outcome assessments: considerations for regulatory decis
by jalin
Elektra Papadopoulos, MD, MPH. Acting Deputy Direc...
Guidance for Clinical Investigators Sponsors and Investigational New D
Guidance for Clinical Investigators Sponsors and Investigational New D
by jade
NOTE A stay is in effect for partsof subsection V...
2011 American Association for Clinical Chemistry
2011 American Association for Clinical Chemistry
by mackenzie
Page 1of 8The Journey to Regulation of Protein-Bas...
Clinical and Nonclinical Inspections
Clinical and Nonclinical Inspections
by claire
n and Research or CBER conducting clinical resear...
1 Pediatric Clinical Investigator Training
1 Pediatric Clinical Investigator Training
by lois-ondreau
GCP: . Tips on Clinical Trial Conduct and . Prepa...
Clinical Trial Data Integrity:
Clinical Trial Data Integrity:
by phoebe-click
Bi. oresearch . Mo. nitoring Program. Jur Strobos...
ClinicalTrials.gov update
ClinicalTrials.gov update
by kimberly
Public Pressure to Enforce Final Rule. TranspariME...
FDA’s Clinical Investigator Course
FDA’s Clinical Investigator Course
by beatrice
Preparing an IND Application: CBER Breakout Sessi...
Regulatory Environment for
Regulatory Environment for
by mila-milly
Alzheimers. Therapeutics . (and Diagnostics). Mar...
Writing and Holding an IND- IIT Development
Writing and Holding an IND- IIT Development
by osullivan
Week 3- Proposing and Conducting a Clinical Trial....
Department of Health and Human Services
Department of Health and Human Services
by daisy
FDA’Daniel R. LevinsonInspector General OEI-0...
Department of Health and Human Services
Department of Health and Human Services
by lam
Daniel R. LevinsonInspector General January 2009 O...
Information Sheet Guidance for Institutional Review Boards Clinical I
Information Sheet Guidance for Institutional Review Boards Clinical I
by anastasia
http://www.fda.gov/ScienceResearch/SpecialTopics/R...
Clinical/Surrogate Endpoints and Innovative Approaches for Catheter Ablation Studies
Clinical/Surrogate Endpoints and Innovative Approaches for Catheter Ablation Studies
by SugarPlumFairy
FDA Perspective. Marco Cannella, PhD. Senior Lead ...
Department of Health and Human Services2 OFFICE OF 2INSPECTOR GENERAL
Department of Health and Human Services2 OFFICE OF 2INSPECTOR GENERAL
by anastasia
Daniel R LevinsonInspector General The mission of ...
UC DAVIS OFFICE OF RESEARCH
UC DAVIS OFFICE OF RESEARCH
by olivia-moreira
Overview of Good Clinical Practices (GCP) . Inves...
1 Structure and mandate of FDA
1 Structure and mandate of FDA
by sherrill-nordquist
Leonard Sacks. Office of Medical Policy. CDER, FD...
Faculty Leonard H. Calabrese, DO
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
The IND and Clinical Trial Management
The IND and Clinical Trial Management
by kittie-lecroy
Frances Richmond . Director International Center ...
FDA Public Workshop – Variant Classification
FDA Public Workshop – Variant Classification
by lindy-dunigan
Session 4: Future directions for data sharing, st...
My Experiences as an FDA Statistician
My Experiences as an FDA Statistician
by aaron
Yeh-Fong Chen, Ph.D. . FDA/CDER/OB/DB3. CBA 2016-...
Afternoon Breakout Session:
Afternoon Breakout Session:
by stefany-barnette
FDA and Regulatory Environment As We Enter the Us...